Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-06-23

Clinical Trial Update: A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily [Phase 3]

View source ↗

Summary

Phase 3 trial comparing GSK1349572 50mg once daily to raltegravir 400mg twice daily completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • GSK1349572
  • Raltegravir (raltegravir)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus I | Phase 3 | Status: COMPLETED | Results posted: 2014-06-23